Outcomes of Dolutegravir Use in Children and Adolescents Living With HIV-1 in Sub-Saharan Africa

July 18-21, 2021; Virtual
Large, retrospective analysis illustrates viral suppression with and tolerability of dolutegravir-based regimens in children and adolescents who were treatment naive or suppressed on previous regimens.
Format: Microsoft PowerPoint (.ppt)
File Size: 242 KB
Released: July 22, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Produced in collaboration with
Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Expert review of interventions to link HIV diagnosis to successful treatment, from Clinical Care Options (CCO)

Nagalingeswaran Kumarasamy, MBBS, FRCP, PhD Released: August 18, 2022

person default Ariel Campos, MD Released: August 18, 2022

Learn from Dr Jonathan Appelbaum about medical challenges faced by aging people with HIV, from Clinical Care Options (CCO)

Jonathan Appelbaum, MD, FACP, AAHIVS
Program Director
Released: August 17, 2022

Expert selections of important HIV data from AIDS 2022, including current and investigational strategies for prevention, ART, comorbidities, and cure from Clinical Care Options (CCO)

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS David A. Wohl, MD Released: August 17, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings